How it works:
Metformin belongs to the biguanide class and is considered first-line therapy for type 2 diabetes. It decreases hepatic glucose production, enhances peripheral insulin sensitivity, and improves glucose uptake in muscle tissue. It does not stimulate insulin secretion, which reduces the risk of hypoglycemia during monotherapy.
The sustained-release formulation provides gradual release of the active ingredient, ensuring stable plasma levels and improved gastrointestinal tolerability.
Recommended for:
Clinical evidence:
Metformin is one of the most extensively studied drugs in endocrinology. Large international clinical trials, including the UKPDS study, demonstrated reduced risk of vascular complications and improved long-term outcomes in patients with type 2 diabetes.
Evidence supports its effectiveness in lowering HbA1c and maintaining durable glycemic control.
Extended-release formulations have been associated with improved tolerability compared to immediate-release forms.
Type 2 diabetes mellitus, particularly in overweight patients. Used to control blood glucose levels, reduce insulin resistance, and help prevent diabetes-related complications. It may be used alone or in combination with insulin or other antidiabetic agents.
The medication should be taken orally with or after meals and swallowed whole with water. Extended-release tablets must not be crushed or chewed. Dosage and duration of therapy are determined individually by a healthcare provider.
Contraindications:
Side effects:
